Delivery Order SPE2DB22D3009-SPE2DB24FAZ02
Award Date
6/21/24
Potential Completion Date
7/15/24
Potential Value
$13K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product, to the U.S. Defense Logistics Agency (DLA). The firm-fixed-price, $9,391.75 contract has a completion date of July 1, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML pharmaceutical product to the Defense Logistics Agency (DLA). The $1,124.56 firm-fixed price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 between Amerisourcebergen and the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a Firm Fixed Price delivery order contract valued at $1,116.57 by the Defense Logistics Agency (DLA) to provide HYPERRAB 300 UNIT/ML VIALML pharmaceuticals. This delivery order is part of a larger Indefinite Delivery Contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
This federal contract award is a $1,039.53 Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a medical product, with a completion date of February 25, 2025. The contract is not designated with a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $4,466.28 firm fixed-price delivery order contract is for the provision of HYPERRAB 300 UNIT/ML VIALML, a pharmaceutical product. The award has no set-aside designation and is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a large pharmaceutical distribution company. The $13,398.48 Firm Fixed Price Delivery Order contract is for the provision of HYPERRAB 300UNIT/ML 1S, a medication. The contract has a completion date of June 10, 2024. Amerisourcebergen holds a much larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop Support Medical, which serves as the...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, is a $37,567.00 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31,...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HYPERRAB 300 UNIT/ML VIAL 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract is a Firm Fixed Price Delivery Order with a ceiling value of $11,245.60 and a completion date of June 13, 2024. The contract is not set aside for any specific business type. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal...
This federal contract award is a delivery order with a firm fixed price of $1,732.55 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is with the Defense Logistics Agency (DLA), a Defense agency, to provide HYPERRAB 300 UNIT/ML VIALML. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award to Amerisourcebergen Drug Corp, Corporate Office Division, is for the supply of a pharmaceutical product, HYPERRAB 300 UNIT/ML VIAL, to the Defense Logistics Agency (DLA). The $4,466.28 firm fixed-price delivery order has a performance period through June 17, 2024. The contract is not designated as a set-aside. Amerisourcebergen, a major pharmaceutical distributor, holds a single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...